Literature PSMA I&T

[1] Weineisen M. et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med, 2015, 56(8):1169-76.
Link: http://jnm.snmjournals.org/content/56/8/1169.long

[2] Fendler WP. Et al. 68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.Eur J Nucl Med Mol Imaging, 2017, 44(6):1014-1024.
Link: https://link.springer.com/article/10.1007%2Fs00259-017-3670-z

[3] Kulkarni HR wt a. PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013. J Nucl Med. 2016, 57(Suppl 3):97S-104S.
Link: http://jnm.snmjournals.org/content/57/Supplement_3/97S.long

[4] von Eyben FE. et al. Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. Eur J Nucl Med Mol Imaging, 2018, 45(3):496-508.
Link: https://link.springer.com/article/10.1007%2Fs00259-017-3895-x

[5] Hermann K. et al. Biodistribution and Radiation Dosimetry for a Probe Targeting Prostate-Specific Membrane Antigen for Imaging and Therapy. J Nucl Med, 2016, 56(6):855-861.
Link: http://jnm.snmjournals.org/content/56/6/855.long

[6] Baum RP. et al. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy. J Nucl Med, 2016, 57(7):1006-1013.
Link: http://jnm.snmjournals.org/content/57/7/1006.long

[7] Kristell C. et al. Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent. Theranostics, 2016, 6(6):849-861
Link: http://www.thno.org/v06p0849.htm

[8] Okamoto S. et al. Radiation Dosimetry for 177Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor Lesions. J Nucl Med, 2017, 58(3):445-450
Link: http://jnm.snmjournals.org/content/58/3/445.long